中恆集團(600252.SH)半年度淨利潤升7.81%至3.63億元
格隆匯8月22日丨中恆集團(600252.SH)發佈2019年半年度報告，實現營業收入18.14億元，同比增長20.04%；歸屬於上市公司股東的淨利潤3.63億元，同比增長7.81%；歸屬於上市公司股東的扣除非經常性損益的淨利潤2.90億元，同比增長11.95%；基本每股收益0.1046元。
2019年上半年國家繼續出台了多項政策，相關政策在醫療器械、醫療健康、醫保、監管等層面全面覆蓋。出台政策之密集、政策影響之廣泛、執行力度之強，使得我國醫藥健康領域沿着深化醫改這一主線繼續推進。在優化藥品結構、降低藥品價格、縮短流通渠道、加大監管力度等因素的綜合作用下，藥企加快轉型升級、提升產品技術含量、構建專業的經營模式顯得越發重要；另外，《健康中國行動（2019-2030年）》的頒佈，再次明確了國家發展中醫藥的決心，提出了針對心腦血管疾病、癌症、慢性呼吸系統疾病、糖尿病重大疾病的防控，對於中醫藥傳出了新的發展信號。
中恆集團積極探索企業的發展路徑，圍繞“產融投”發展戰略，勇當自治區“強龍頭，補鏈條，聚集羣”戰略的實踐者，優化經營管理、推動科技創新、加快企業戰略轉型，促使企業從生產型向研發型轉變、從產品經營向資本相結合。實現企業的高質量發展。
報告期內，製藥公司實現營業收入17.25億元，同比增長20.48%，利潤總額3.74億元，同比增長18.78%。雙錢公司實現營業收入7515萬元，同比增長14.73%，利潤總額867萬元，同比增長127.56%。
為進一步做強做大中恆集團，整合研發資源，創建更多研發平台，提升研發實力，公司以堅持創新發展、堅持市場導向、堅持產學研聯動為原則，設立研發大平台，整合中科院、北京大學、四川大學、中醫科學院等高等院校和研發機構資源，全力打造藥品食品研發大平台，促進公司整體研發水平的提升。
製藥公司紮實開展血栓通臨牀研究，充實產品在學術推廣中所需的證據鏈，延長產品生命周期；同時對於藥品創新研究不放鬆，治療自身免疫性疾病一類新藥(SKLB677)研究、中藥經典名方的藥學研究等項目也在有序進行。報告期內獲得10件發明專利授權並取得專利證書。雙錢公司以消費者為導向，根據市場的需求，針對龜苓膏以及雙錢飲品系列進行持續的工藝改進，並研製了不同口味的產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
